Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 2/2016

01-04-2016 | Short Research Report

Treating Staphylococcus aureus infections in an intensive care unit at a University Hospital in Brazil

Authors: Marina Gimenes, Tânia Pereira Salci, Maria Cristina B. Tognim, Vera Lúcia Dias Siqueira, Silvana Martins Caparroz-Assef

Published in: International Journal of Clinical Pharmacy | Issue 2/2016

Login to get access

Abstract

Background Optimizing antimicrobial therapy is important for treating patients who are critically ill with Staphylococcus aureus infection, and susceptibility tests are necessary. Objective The aim of the present study was to evaluate antibacterial therapy after susceptibility testing of S. aureus infections. Setting The setting was an intensive care unit at a University Hospital in Brazil. Methods An observational and retrospective study was conducted over 6 years. The antimicrobials that were used for S. aureus infection treatment were calculated as the defined daily dose per 1000 patient-days (DDD1000). Antimicrobial susceptibility data were obtained by reviewing bacteriological tests. Patient profiles and treatment were determined by analyzing patient charts. Results Methicillin-resistant S. aureus (MRSA) was prevalent in this study (76.13 %). Patients who were infected with MRSA had total antimicrobial consumption that was three-times higher (9567.2 DDD1000) than patients who were infected with methicillin-susceptible S. aureus (MSSA; 3101.1 DDD1000). The average length of stay in the intensive care unit was 19 days (interquartile range 17 days) for MSSA and 20 days (interquartile range 20 days) for MRSA. Mortality in patients who were infected with MSSA was higher (52.17 %) than in patients who were infected with MRSA (33.80 %), and de-escalation was not identified in 73.90 % of MSSA patients.
Literature
1.
go back to reference Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J, Gomersall C, Sakr Y, Reinhart K. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302(21):2323–9.CrossRefPubMed Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J, Gomersall C, Sakr Y, Reinhart K. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302(21):2323–9.CrossRefPubMed
2.
go back to reference Hadler JL, Petit S, Mandour M, Cartter ML. Trends in invasive infection with methicillin-resistant Staphylococcus aureus, Connecticut, USA, 2001–2010. Emerg Infect Dis. 2012;18(6):917–24.CrossRefPubMedPubMedCentral Hadler JL, Petit S, Mandour M, Cartter ML. Trends in invasive infection with methicillin-resistant Staphylococcus aureus, Connecticut, USA, 2001–2010. Emerg Infect Dis. 2012;18(6):917–24.CrossRefPubMedPubMedCentral
3.
go back to reference Rossi F. The challenges of antimicrobial resistance in Brazil. Clin Infect Dis. 2011;52(9):1138–43.CrossRefPubMed Rossi F. The challenges of antimicrobial resistance in Brazil. Clin Infect Dis. 2011;52(9):1138–43.CrossRefPubMed
4.
go back to reference Luna CM, Rodríguez-Noriega E, Bavestrello L, Gotuzzo E. Treatment of methicillin-resistant Staphylococcus aureus in Latin America. Braz J Infect Dis. 2010;14(Suppl 2):S119–27.CrossRefPubMed Luna CM, Rodríguez-Noriega E, Bavestrello L, Gotuzzo E. Treatment of methicillin-resistant Staphylococcus aureus in Latin America. Braz J Infect Dis. 2010;14(Suppl 2):S119–27.CrossRefPubMed
5.
go back to reference Niederman MS, Soulountsi V. De-escalation therapy: is it valuable for the management of ventilator-associated pneumonia? Clin Chest Med. 2011;32(3):517–34.CrossRefPubMed Niederman MS, Soulountsi V. De-escalation therapy: is it valuable for the management of ventilator-associated pneumonia? Clin Chest Med. 2011;32(3):517–34.CrossRefPubMed
6.
go back to reference Weiss E, Zahar JR, Lesprit P, Ruppe E, Leone M, Chastre J, Lucet JC, et al. Elaboration of a consensual definition of de-escalation allowing a ranking of β-lactams. Clin Microbiol Infect. 2015;21(7):649.e1–10.CrossRef Weiss E, Zahar JR, Lesprit P, Ruppe E, Leone M, Chastre J, Lucet JC, et al. Elaboration of a consensual definition of de-escalation allowing a ranking of β-lactams. Clin Microbiol Infect. 2015;21(7):649.e1–10.CrossRef
7.
go back to reference Kim SH, Kim KH, Kim HB, Kim NJ, Kim EC, Oh MD, et al. Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2008;52(1):192–7.CrossRefPubMedPubMedCentral Kim SH, Kim KH, Kim HB, Kim NJ, Kim EC, Oh MD, et al. Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2008;52(1):192–7.CrossRefPubMedPubMedCentral
8.
go back to reference Bal AM, Garau J, Gould IM, Liao CH, Mazzei T, Nimmo GR, et al. Vancomycin in the treatment of meticillin-resistant Staphylococcus aureus (MRSA) infection: end of an era? J Glob Antimicrob Resist. 2013;1(1):23–30.CrossRef Bal AM, Garau J, Gould IM, Liao CH, Mazzei T, Nimmo GR, et al. Vancomycin in the treatment of meticillin-resistant Staphylococcus aureus (MRSA) infection: end of an era? J Glob Antimicrob Resist. 2013;1(1):23–30.CrossRef
9.
go back to reference Lafaurie M, Porcher R, Donay JL, Touratier S, Molina JM. Reduction of fluoroquinolone use is associated with a decrease in methicillin-resistant Staphylococcus aureus and fluoroquinolone-resistant Pseudomonas aeruginosa isolation rates: a 10 year study. J Antimicrob Chemother. 2012;67(4):1010–5.CrossRefPubMed Lafaurie M, Porcher R, Donay JL, Touratier S, Molina JM. Reduction of fluoroquinolone use is associated with a decrease in methicillin-resistant Staphylococcus aureus and fluoroquinolone-resistant Pseudomonas aeruginosa isolation rates: a 10 year study. J Antimicrob Chemother. 2012;67(4):1010–5.CrossRefPubMed
10.
go back to reference Ribas RM, Freitas C, Gontijo-Filho PP. Nosocomial methicillin-resistant Staphylococcus aureus bacteremia in a tertiary care hospital: risk factors, overall mortality and antimicrobial resistance. Int J Med Sci. 2009;1(10):412–7. Ribas RM, Freitas C, Gontijo-Filho PP. Nosocomial methicillin-resistant Staphylococcus aureus bacteremia in a tertiary care hospital: risk factors, overall mortality and antimicrobial resistance. Int J Med Sci. 2009;1(10):412–7.
Metadata
Title
Treating Staphylococcus aureus infections in an intensive care unit at a University Hospital in Brazil
Authors
Marina Gimenes
Tânia Pereira Salci
Maria Cristina B. Tognim
Vera Lúcia Dias Siqueira
Silvana Martins Caparroz-Assef
Publication date
01-04-2016
Publisher
Springer International Publishing
Published in
International Journal of Clinical Pharmacy / Issue 2/2016
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-016-0273-x

Other articles of this Issue 2/2016

International Journal of Clinical Pharmacy 2/2016 Go to the issue